Immuno-affinity Capture Followed by TMPP N-Terminus Tagging to Study Catabolism of Therapeutic Proteins.
Characterization of in vitro and in vivo catabolism of therapeutic proteins has increasingly become an integral part of discovery and development process for novel proteins. Unambiguous and efficient identification of catabolites can not only facilitate accurate understanding of pharmacokinetic profiles of drug candidates, but also enables follow up protein engineering to generate more catabolically stable molecules with improved properties (pharmacokinetics and pharmacodynamics). Immunoaffinity capture (IC) followed by top-down intact protein analysis using either matrix-assisted laser desorption/ionization or electrospray ionization mass spectrometry analysis have been the primary methods of choice for catabolite identification. However, the sensitivity and efficiency of these methods is not always sufficient for characterization of novel proteins from complex biomatrices such as plasma or serum. In this study a novel bottom-up targeted protein workflow was optimized for analysis of proteolytic degradation of therapeutic proteins. Selective and sensitive tagging of the alpha-amine at the N-terminus of proteins of interest was performed by immunoaffinity capture of therapeutic protein and its catabolites followed by on-bead succinimidyloxycarbonylmethyl tri-(2,4,6-trimethoxyphenyl N-terminus (TMPP-NTT) tagging. The positively charged hydrophobic TMPP tag facilitates unambiguous sequence identification of all N-terminus peptides from complex tryptic digestion samples via data dependent liquid chromatgraphy-tandem mass spectroscopy. Utility of the workflow was illustrated by definitive analysis of in vitro catabolic profile of neurotensin human Fc (NTs-huFc) protein in mouse serum. The results from this study demonstrated that the IC-TMPP-NTT workflow is a simple and efficient method for catabolite formation in therapeutic proteins.
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. , South San Francisco, California 94080, United States.
Majlinda
0000-0002-3078-2395
M
Kullolli
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. , South San Francisco, California 94080, United States.
Dan A
DA
Rock
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. , South San Francisco, California 94080, United States.
Ji
J
Ma
D000595:Amino Acid Sequence; D000818:Animals; D001711:Biotransformation; D002853:Chromatography, Liquid; D006801:Humans; D007163:Immunosorbent Techniques; D051379:Mice; D009496:Neurotensin / Q000008:administration & dosage / Q000097:blood*; D009861:Onium Compounds / Q000737:chemistry*; D009943:Organophosphorus Compounds / Q000737:chemistry*; D010446:Peptide Fragments / Q000097:blood* / Q000737:chemistry; D013194:Staining and Labeling / Q000379:methods*; D055672:Static Electricity; D053719:Tandem Mass Spectrometry; D014357:Trypsin / Q000737:chemistry
C000608117:N-succinimidyloxycarbonylmethyl tris(2,4,6-trimethoxyphenyl)phosphonium; D009861:Onium Compounds; D009943:Organophosphorus Compounds; D010446:Peptide Fragments; D009496:Neurotensin; D014357:Trypsin
N-succinimidyloxycarbonylmethyl tri-(2,4,6-trimethoxyphenyl) phosphonium; immunoprecipitation; on-bead tagging; proteolytic degradation